Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ablynx NV (NASDAQ: ABLX).

Full DD Report for ABLX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ABLX)

Merger Arbitrage Mondays - June 18, 2018
Merger activity increased last week with two new deals announced and five pending deals closing. Several deals with large spreads on account of regulatory hurdles including Bayer's acquisition of Monsanto, AT&T's (T) acquisition of Time Warner and China Oceanwide's acquisition of Genworth ...
Source: SeekingAlpha
Date: June, 19 2018 08:13
Wired News - Sanofi and Ablynx Announce Results of the Initial Tender Offer Period and Commencement of Squeeze-Out Tender Period
LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want access to our free research report on Sanofi American Depositary Shares (NYSE: SNY ) ("Sanofi"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SNY as the Company's late...
Source: ACCESSWIRE IA
Date: May, 16 2018 07:00
How Do Listed Companies Perform With A U.S. IPO?
US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded companies are currently scheduled to complete initial ...
Source: SeekingAlpha
Date: April, 19 2018 23:18
Wall Street Breakfast: Tax Day At The Supreme Court
A closely-watched showdown at the U.S. Supreme Court today will determine whether states can force out-of-state online retailers to collect sales tax. South Dakota is asking the nine justices to overturn a 1992 Supreme Court precedent, appealing a lower court decision that favored ...
Source: SeekingAlpha
Date: April, 17 2018 06:59
Big Biotech Swings: 2016 IPO AveXis Pops 82%, 2018 IPO Menlo Drops 77%
Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs . Betting on a biotech buyout... The billion-dollar biotech buyouts continue. News broke on Monday that Novartis (NVS) agreed to buy gene therapy bitoech AveXis (AVXS) for $218 per s...
Source: SeekingAlpha
Date: April, 10 2018 06:22
Sanofi to commence previous tender offers to acquire Ablynx on April 4
Sanofi (NYSE: SNY ) will commence the previous tender offers to acquire all of the Ablynx's (NASDAQ: ABLX ) outstanding shares for €45.00 per share/ADS, warrants at €18.66 - 41.79 per warrant and convertible bonds at €393,700.78 on April 4. More n...
Source: SeekingAlpha
Date: March, 29 2018 07:17
Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla
Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss AbbVie ( ABBV ), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, ...
Source: SeekingAlpha
Date: February, 19 2018 08:00
Sanofi licenses two additional Nanobody candidates from Ablynx
Ablynx (NASDAQ: ABLX ) announces that Sanofi (NYSE: SNY ) has exercised its option to license two additional target combinations under their July 2017 collaboration aimed at developing and commercializing Nanobody-based therapeutics for immune-mediated inflammatory disorders. More news o...
Source: SeekingAlpha
Date: February, 16 2018 09:05
BioSci Rounds Report For Feb. 1, 2018
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) Trading Analytics On Feb. 1, 2018, three highly promising biosciences topped Integrated BioSci Investing (&#x...
Source: SeekingAlpha
Date: February, 02 2018 04:26
Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?
Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofi’s bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to...
Source: SeekingAlpha
Date: January, 31 2018 03:09

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1753.1352.9053.1752.8536,085

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-1220160833.0592Cover
2018-06-1110160216.7774Cover
2018-06-0816917099.4118Short
2018-06-0713543930.7517Cover
2018-06-069034026.4706Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABLX.


About Ablynx NV (NASDAQ: ABLX)

Logo for Ablynx NV (NASDAQ: ABLX)

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck amp Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

 

Current Share Structure

     


    Recent Filings from (NASDAQ: ABLX)

    Amendment to a previously filed SC TO-T
    Filing Type: SC TO-T/AFiling Source: edgar
    Filing Date: May, 14 2018
    Amendment to a previously filed SC 14D9
    Filing Type: SC 14D9/AFiling Source: edgar
    Filing Date: May, 14 2018
    Amendment to a previously filed SC TO-T
    Filing Type: SC TO-T/AFiling Source: edgar
    Filing Date: May, 07 2018
    Amendment to a previously filed SC 14D9
    Filing Type: SC 14D9/AFiling Source: edgar
    Filing Date: May, 07 2018
    Amendment to a previously filed 20-F
    Filing Type: 20-F/AFiling Source: edgar
    Filing Date: April, 05 2018
    Solicitation/recommendation statements
    Filing Type: SC 14D9Filing Source: edgar
    Filing Date: April, 04 2018
    Tender offer schedule and amendment filed by a third party
    Filing Type: SC TO-TFiling Source: edgar
    Filing Date: April, 04 2018
    Written public communication relating to an issuer or third party tender offer not by the subject company
    Filing Type: SC TO-CFiling Source: edgar
    Filing Date: March, 29 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 29 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 27 2018

     

     


    Daily Technical Chart for (NASDAQ: ABLX)

    Daily Technical Chart for (NASDAQ: ABLX)


    Stay tuned for daily updates and more on (NASDAQ: ABLX)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ABLX)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABLX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ABLX and does not buy, sell, or trade any shares of ABLX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/